Small molecule · Inhibitor of epidermal growth factor receptor (EGFR) · developed by Takeda Pharms Usa
Mobocertinib is an orally available kinase inhibitor that irreversibly binds and inhibits EGFR exon 20 insertion mutations, with secondary activity against other EGFR family members HER2 and HER4. It is studied in non-small cell lung cancer, including advanced and metastatic disease with EGFR exon 20 insertion mutations.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 3, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04129502 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Completed | TAK |
| NCT03807778 | Phase 1 | Non-Small Cell Lung Cancer | Active not recruiting | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Non-Small Cell Lung CancerAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →